Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis.
Bottom Line: The results showed that the vaccine arm significantly extended primary endpoint median overall survival compared with control group (p<0.00001) (HR 0.760; 95% CI 0.644 to 0.896; p=0.001).Three subgroup patients with tumour vaccine at 1-year, 2-year and 3-year survival rates also gained significant benefits compared with their corresponding control group (p=0.0004, 0.03 and 0.19, respectively).A few severe adverse effects occurred in the tumour vaccine group, but fewer side effects were observed in the vaccine group compared with the control group (p<0.00001).
Affiliation: Biotherapy Center, General Hospital of Beijing Military Command, Beijing, People's Republic of China.Show MeSH
Related in: MedlinePlus
Mentions: The vaccine treatment group showed a favourable result when subjected to analysis of the ORR which was denoted by complete response rates (CR) and partial rates (PR), compared with the corresponding control arm (OR 1.36, 95% CI 1.02 to 1.80, p=0.05).17182223 Indeed, vaccine immunotherapy generated a statistical difference compared with the control arm in four trials including 849 patients. Within the random effects model used in ORR analysis, no evidence of heterogeneity among the individual studies was observed (I2=15%, p=0.05; figure 3).
Affiliation: Biotherapy Center, General Hospital of Beijing Military Command, Beijing, People's Republic of China.